share_log

HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $20 Price Target

Benzinga ·  Apr 25 19:29

HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $20 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment